Immune checkpoint inhibitors plus anti-angiogenesis in patients with resected high-risk hepatitis B virus-associated hepatocellular carcinoma

Table 4 Impact of hepatic impairment and medication use on recurrence-free survival and overall survival, n (%)

	Yes	No	OR (95%CI)	P value
RFS events occurred
Any degree of hepatic impairment			5.200 (1.068-25.309)	0.041
Yes	8 (26.7)	5 (16.7)
No	4 (13.3)	13 (43.3)
Medication interruption events for any reason			2.000 (0.440-9.096)	0.370
Yes	8 (26.7)	9 (30)
No	4 (13.3)	9 (30)
Medication duration less than median			0.571 (0.130-2.503)	0.458
Yes	7 (23.3)	8 (26.7)
No	5 (16.7)	10 (33.3)
OS events occurred
Any degree of hepatic impairment			2.909 (0.234-36.164)	0.406
Yes	2 (6.7)	11 (36.7)
No	1 (3.3)	16 (53.3)
Medication interruption events for any reason			1.600 (0.129-19.838)	0.714
Yes	2 (6.7)	15 (50.0)
No	1 (3.3)	12 (40.0)
Medication duration less than median			0.464 (0.037-5.749)	0.550
Yes	2 (6.7)	13 (43.3)
No	1 (3.3)	14 (46.7)

OR: Odds ratio; CI: Confidence interval; RFS: Recurrence-free survival; OS: Overall survival.